{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:39:23Z","timestamp":1722890363866},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ramb.2012.08.003","type":"journal-article","created":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T07:34:00Z","timestamp":1368862440000},"page":"220-232","source":"Crossref","is-referenced-by-count":4,"title":["Leucemia mieloide cr\u00f4nica"],"prefix":"10.1016","volume":"59","author":[{"name":"Associa\u00e7\u00e3o Brasileira de Hematologia e Hemoterapia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Sociedade Brasileira de Patologia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Sociedade Brasileira de Pediatria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.ramb.2012.08.003_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/mdp143","article-title":"Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Baccarani","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ramb.2012.08.003_bib0020","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0025","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.ramb.2012.08.003_bib0030","first-page":"803","article-title":"Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia","volume":"4","author":"de Lemos","year":"2005","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.ramb.2012.08.003_bib0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-009-0822-7","article-title":"Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts","volume":"89","author":"Sharma","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0040","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood-2007-02-074252","article-title":"Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia","volume":"110","author":"Kreil","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1751-553X.2009.01143.x","article-title":"Prognostic relevance of 9q34 deletion and the suppressor of cytokine signalling-1 in CML patients","volume":"32","author":"Ghaith","year":"2010","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0165-4608(01)00412-5","article-title":"Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis","volume":"128","author":"Cohen","year":"2001","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.ramb.2012.08.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.26147","article-title":"Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib","volume":"117","author":"Quint\u00e1s-Cardama","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ramb.2012.08.003_bib0060","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quint\u00e1s-Cardama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0065","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V98.6.1732","article-title":"Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia","volume":"98","author":"Huntly","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0070","first-page":"952","article-title":"Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia","volume":"91","author":"Fourouclas","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ramb.2012.08.003_bib0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cancergencyto.2007.06.013","article-title":"Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia","volume":"178","author":"Vaz de Campos","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.ramb.2012.08.003_bib0080","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0085","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1200\/JCO.2009.26.7963","article-title":"Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis","volume":"28","author":"Castagnetti","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0090","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/10428190701618284","article-title":"Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome","volume":"48","author":"Landstrom","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ramb.2012.08.003_bib0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cancergencyto.2006.10.006","article-title":"On the genesis and prognosis of variant translocations in chronic myeloid leukemia","volume":"173","author":"Gorusu","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.ramb.2012.08.003_bib0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000331472","article-title":"Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients","volume":"127","author":"Meggyesi","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0105","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3324\/haematol.2009.014712","article-title":"Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"95","author":"Kim","year":"2010","journal-title":"Hematologica"},{"key":"10.1016\/j.ramb.2012.08.003_bib0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-4800(90)90008-2","article-title":"Prognostic Significance of Secondary Cytogenetic Changes and Nonspecific Cross-reacting Antigen (NCA) in Patients with Ph-Positive Chronic Myeloid Leukemia","volume":"52","author":"Haus","year":"1990","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.kjms.2010.09.001","article-title":"Additional chromosome abnormalities in chronic myeloid leukemia","volume":"27","author":"Hsiao","year":"2011","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.ramb.2012.08.003_bib0120","first-page":"381","article-title":"A significance of additional chromosomal aberrations and other variables on post transplantation outcome of patients with CML","volume":"52","author":"Vranov\u00e1","year":"2005","journal-title":"Neoplasma"},{"key":"10.1016\/j.ramb.2012.08.003_bib0125","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0130","first-page":"469","article-title":"Presentating phases of chronic myeloid leukaemia","volume":"19","author":"Ahmed","year":"2009","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.ramb.2012.08.003_bib0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0037-1963(03)70045-6","article-title":"Advanced-phase chronic myeloid leukemia","volume":"40","author":"Cortes","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0140","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal","volume":"106","author":"Cortes","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ramb.2012.08.003_bib0145","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ramb.2012.08.003_bib0150","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl2","key":"10.1016\/j.ramb.2012.08.003_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428190903370387","article-title":"State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment","volume":"50","author":"Aguayo","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ramb.2012.08.003_bib0160","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.2000.02366.x","article-title":"Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia","volume":"111","author":"Bonifazi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0165","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2011-01-330332","article-title":"Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study","volume":"118","author":"Corm","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0170","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving 22 imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ramb.2012.08.003_bib0175","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2009.016766","article-title":"Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia","volume":"95","author":"Deenik","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ramb.2012.08.003_bib0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"Forrest","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.ramb.2012.08.003_bib0185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0037-1963(03)70038-9","article-title":"Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy","volume":"40","author":"Hasford","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1756-8722-2-30","article-title":"Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study","volume":"2","author":"Lee","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0195","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/10428190701824585","article-title":"Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country","volume":"49","author":"Rajappa","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ramb.2012.08.003_bib0200","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ramb.2012.08.003_bib0205","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2- year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0210","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ramb.2012.08.003_bib0215","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0220","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1080\/10428190802578841","article-title":"Differences in hematological and nonhematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia","volume":"49","author":"Breccia","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ramb.2012.08.003_bib0225","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1590\/S1807-59322009000800004","article-title":"Influence of late treatment on how chronic myeloid leukemia responds to imatinib","volume":"64","author":"Scerni","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.ramb.2012.08.003_bib0230","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0235","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0240","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2007.13.2373","article-title":"Party on CML. Long-term outcome of complete cytogenetic responders after imatinib 400mg in late chronic phase, philadelphiapositive chronic myeloid leukemia: the GIMEMA Working Party on CML","volume":"26","author":"Palandri","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0245","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ramb.2012.08.003_bib0250","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1182\/blood-2008-10-184960","article-title":"Failure to achieve a complete hematologic response at the time of a major cytogenetic response with secondgeneration tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase","volume":"113","author":"Fava","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0255","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure of treatment with secondgeneration tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ramb.2012.08.003_bib0260","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.leu.2403664","article-title":"Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse","volume":"19","author":"Marin","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ramb.2012.08.003_bib0265","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s12185-011-0774-2","article-title":"Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical study","volume":"93","author":"Furukawa","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0270","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0275","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2404139","article-title":"Limited clinical value of regular bone marrow cytogenetic analysis in imatinibtreated chronic phase CML patients monitored by RQ-PCR for BCR-ABL","volume":"20","author":"Ross","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ramb.2012.08.003_bib0280","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ramb.2012.08.003_bib0285","first-page":"49","article-title":"Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy","volume":"89","author":"Lange","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.ramb.2012.08.003_bib0290","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/cncr.25678","article-title":"Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond","volume":"117","author":"Lima","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ramb.2012.08.003_bib0295","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0300","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ramb.2012.08.003_bib0305","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinibresistant and-intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0310","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ramb.2012.08.003_bib0315","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1002\/cncr.25351","article-title":"Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant","volume":"116","author":"Koren-Michowitz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ramb.2012.08.003_bib0320","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerlyAMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia inchronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0325","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinibis effective in patients with chronic myeloid leukemia in chronic phase afterimatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0330","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemiafollowing failure of imatiniband dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ramb.2012.08.003_bib0335","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0340","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0345","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0350","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0355","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0360","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","article-title":"Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0365","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0370","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0375","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ramb.2012.08.003_bib0380","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0385","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Longterm outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0390","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.leukres.2010.12.006","article-title":"BCR-ABL1 mutations in patients with imatinibresistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay","volume":"35","author":"Ono","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.ramb.2012.08.003_bib0395","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0400","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"BcrAbl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0405","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0410","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0415","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0420","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.2011.35.0934","article-title":"Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy","volume":"29","author":"Parker","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0425","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2141.2002.03705.x","article-title":"Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia","volume":"118","author":"Wang","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0430","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ramb.2012.08.003_bib0435","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0440","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0445","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2403077","article-title":"FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib","volume":"17","author":"Reinhold","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ramb.2012.08.003_bib0450","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1080\/10428190902930496","article-title":"New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcrabl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"50","author":"Mascarenhas","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ramb.2012.08.003_bib0455","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ramb.2012.08.003_bib0460","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0465","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0470","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/bmt.2008.441","article-title":"Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients","volume":"44","author":"Burke","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ramb.2012.08.003_bib0475","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.leukres.2011.01.001","article-title":"Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia","volume":"35","author":"Luo","year":"2011","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.ramb.2012.08.003_bib0480","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ramb.2012.08.003_bib0485","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbmt.2010.06.019","article-title":"Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience","volume":"17","author":"Boehm","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ramb.2012.08.003_bib0490","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.leukres.2009.04.036","article-title":"Second generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib","volume":"34","author":"Breccia","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.ramb.2012.08.003_bib0495","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ramb.2012.08.003_bib0500","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin Padiatr"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"language":"pt","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0104423013000614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0104423013000614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T22:15:45Z","timestamp":1595801745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0104423013000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0104423013000614"],"URL":"https:\/\/doi.org\/10.1016\/j.ramb.2012.08.003","relation":{},"ISSN":["0104-4230"],"issn-type":[{"type":"print","value":"0104-4230"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}